智通财经APP获悉，在美国食品药品监督管理局 (FDA)决定将礼来公司 (LLY.US)的替西帕肽 (Tirzepatide)从药品短缺清单中移除后，一起针对此次除名举措的诉讼引发了Hims & Hers Health (HIMS.US)周一交易上涨 ...

The proposal, unveiled at the government's International Investment Summit today is headlined by the creation of a UK biotech ...

Analyst David Larsen from BTIG maintained a Buy rating on LifeMD (LFMD – Research Report) and keeping the price target at $12.00. David ...

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...

The FDA said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of ...

The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and ...

Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Monday after the U.S. Food and Drug Administration said it would ...

The agency agreed in court to allow compounding companies to continue producing copycat versions of Lilly’s fast-selling medicines while it reevaluates its recent decision to declare the drugs back in ...

The reconsideration follows an Oct. 11 lawsuit that prompted U.S. District Judge Mark Pittman to temporarily halt legal proceedings to give the FDA time to reassess its ruling.

In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...

The FDA's decision came in response to a lawsuit filed in federal court in Fort Worth, Texas, by the Outsourcing Facilities Association, a trade association focused on ensuring access to compounded ...

The FDA resolved the shortage of Eli Lilly's tirzepatide, but may revisit allowing compounding pharmacies to make copies, ...